

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

06 Jul 2026

### Comparative bioequivalence study of the Nicorandil 20-mg tablets manufactured by Modava Pharmaceutical company

#### Protocol summary

##### Study aim

Examining the equivalency of domestically produced tablet formulations with brand samples

##### Design

Cross-over unblinded randomization

##### Settings and conduct

The number of 24 healthy volunteers in the age range of 18-60 years and the weight range of  $18 < \text{BMI} < 30$ , male, who are randomly and voluntarily selected through public notification. 1 tablet is taken fasting and blood is taken at 15 time points. A week later, the process is repeated for the external medicine

##### Participants/Inclusion and exclusion criteria

The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase ( $\gamma$ -GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form

##### Intervention groups

After taking a pill for internal production, 3 milliliters of blood will be collected from the volunteer in 15 time intervals for 48 hours. A week later, the process is repeated for a brand sample pill. The drug concentration is measured in plasma

##### Main outcome variables

Studying the Drug pharmacokinetic parameters

#### General information

##### Reason for update

##### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20130313012810N6**

Registration date: **2022-12-25, 1401/10/04**

Registration timing: **prospective**

Last update: **2022-12-25, 1401/10/04**

Update count: **0**

#### Registration date

2022-12-25, 1401/10/04

#### Registrant information

##### Name

Hamed Hamishehkar

##### Name of organization / entity

Drug Applied Research Center, Tabriz University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 1336 3311

##### Email address

hamishehkar.hamed@gmail.com

#### Recruitment status

**Recruitment complete**

#### Funding source

#### Expected recruitment start date

2023-01-10, 1401/10/20

#### Expected recruitment end date

2023-01-18, 1401/10/28

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

Comparative bioequivalence study of the Nicorandil 20-mg tablets manufactured by Modava Pharmaceutical

company

#### Public title

Comparative bioequivalence study of the Nicorandil 20-mg tablets manufactured by Modava Pharmaceutical company

#### Purpose

Other

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase ( $\gamma$ -GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form

##### Exclusion criteria:

History of allergic or adverse reaction to nicorandil or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg. smokers People who have participated in other clinical studies or bioequivalence studies within 3 months before the first day of use Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s)

#### Age

From **18 years** old to **60 years** old

#### Gender

Male

#### Phase

Bioequivalence

#### Groups that have been masked

*No information*

#### Sample size

Target sample size: **24**

#### Randomization (investigator's opinion)

N/A

#### Randomization description

#### Blinding (investigator's opinion)

Not blinded

#### Blinding description

#### Placebo

Not used

#### Assignment

Crossover

#### Other design features

#### Secondary Ids

empty

#### Ethics committees

#### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Tabriz University of Medical Sciences

##### Street address

Daneshgah St. Drug Applied Research Center

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5165665811

#### Approval date

2022-12-19, 1401/09/28

#### Ethics committee reference number

IR.TBZMED.REC.1401.850

#### Health conditions studied

#### 1

#### Description of health condition studied

-

#### ICD-10 code

#### ICD-10 code description

#### Primary outcomes

#### 1

#### Description

Plasma concentration of the drug

#### Timepoint

13 sampling time till 8 h

#### Method of measurement

LCMSMS

#### Secondary outcomes

empty

#### Intervention groups

#### 1

#### Description

Intervention group: Intervention group: This study examines the bioequivalence of nicorandil tablets produced by a domestic company with a foreign brand sample. We have only one intervention group and there is no control group. The intervention group, which includes healthy, fasting male volunteers, will receive a single dose, a 20 mg tablet manufactured by the pharmaceutical company Modava and Merck brand, in two 8-hour periods with an interval of one week, on the day of the study. And in 13 different time periods up to 8 hours after taking the medicine, blood samples will be taken from the volunteers in the amount of 3 ml each time, that is, a total of 39 ml within 8 hours. The training that will be given to the volunteers includes avoiding the

consumption of drinks containing alcohol and xanthine and other interfering drugs in the prescription drug from 48 hours before the start of the study until the end of the study.

**Category**

N/A

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Drug Applied Research Center, Tabriz University of Medical Sciences

**Full name of responsible person**

Hamed Hamishehkar

**Street address**

Drug Applied Research Center, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51656-65811

**Phone**

+98 41 3336 3311

**Email**

hamishehkar.hamed@gmail.com

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Modava Pharmaceutical Company

**Full name of responsible person**

Asghar Heydari

**Street address**

5th floor, Shafayab Building, No. 275, Beheshti St.

**City**

Tehran

**Province**

East Azarbaijan

**Postal code**

1514617714

**Phone**

+98 21 8817 5119

**Email**

info@modavaco.com

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Modava Pharmaceutical Company

**Proportion provided by this source**

100

**Public or private sector**

Private

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Industry

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Drug Applied Research Center, Tabriz University of Medical Sciences

**Full name of responsible person**

Hamed Hamishehkar

**Position**

professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Drug Applied Research Center, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51656-65811

**Phone**

+98 41 3336 3181

**Fax**

+98 41 3336 3311

**Email**

hamishehkar.hamed@gmail.com

**Web page address**

http://darc.tbzmed.ac.ir/

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Drug Applied Research Center, Tabriz University of Medical Sciences

**Full name of responsible person**

Hamed Hamishehkar

**Position**

professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Drug Applied Research Center, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan  
**Postal code**  
51656-65811  
**Phone**  
+98 41 3336 3181  
**Fax**  
+98 41 3336 3311  
**Email**  
hamishehkar.hamed@gmail.com  
**Web page address**  
<http://darc.tbzmed.ac.ir/>

**City**  
Tabriz  
**Province**  
East Azarbaijan  
**Postal code**  
51656-65811  
**Phone**  
+98 41 3336 3181  
**Fax**  
**Email**  
hamishehkar.hamed@gmail.com  
**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Drug Applied Research Center, Tabriz University of  
Medical Sciences  
**Full name of responsible person**  
Hamed Hamishehkar  
**Position**  
professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Medical Pharmacy  
**Street address**  
Drug Applied Research Center, Tabriz University of  
Medical Sciences

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to  
make this available

### Study Protocol

No - There is not a plan to make this available

### Statistical Analysis Plan

No - There is not a plan to make this available

### Informed Consent Form

No - There is not a plan to make this available

### Clinical Study Report

No - There is not a plan to make this available

### Analytic Code

No - There is not a plan to make this available

### Data Dictionary

No - There is not a plan to make this available